Tag: high-grade B-cell lymphoma therapy

Home / high-grade B-cell lymphoma therapy

Categories

Epcoritamab-bysp is approved by FDA for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma

July 2023: The Food and Drug Administration gave accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise spec...
high-grade-b-cell-lymphoma-therapy

Scan the code